Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Competitive bidding redux

This article was originally published in The Gray Sheet

Executive Summary

CMS' second stab at a competitive bidding program for durable medical equipment, prosthetics, orthotics and supplies (DMEPOS) will begin its first round in late October; registration for the 60-day bidding round will begin later this month, the agency says. Congress halted the controversial program in July 2008 just as Medicare began honoring the original winning supplier contracts (1"The Gray Sheet" June 1, 2009). Bids will be accepted in nine geographic areas, this time excluding Puerto Rico. Negative pressure wound therapy and group 3 complex rehabilitation power wheel chair products are also off the first-round bidding list

You may also be interested in...

Competitive Bidding Hurdles Highlight Difficulties Of Curbing Device Costs

The fits and starts in establishing a Medicare competitive bidding program for durable medical equipment illustrate the challenges to reducing federal spending on medical devices, speakers at a May 22 Institute of Medicine workshop said

Sandoz Denosumab Biosimilar Progressing Faster Than Anticipated

Sandoz announced more than a year ago that its GP2411 biosimilar denosumab candidate had entered the clinic. Management provided an update on its progress at the recent Virtual Meet Novartis Management Investor Event.

Dr Reddy's Adds To OTC Portfolio With Glenmark Deal

Dr Reddy's is poised to expand its OTC offering in Russia and certain CIS countries by snapping up a basket of allergy brands from fellow Indian firm Glenmark.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts